Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is In the Details
One of the most important studies presented at ASCO 2018 showed that endocrine therapy alone was noninferior to endocrine therapy plus chemotherapy in women with estrogen receptor (ER)-positive, HER2-negative, node-negative early-stage breast cancer and an intermediate risk score (score, 11-25) on the Oncotype DX gene-expression assay for breast cancer.
“Application of this test in this population could spare chemotherapy in about 70% of patients and select chemotherapy for about 30%,” said lead investigator of the study, Joseph A. Sparano, MD, Associate Director for Clinical Research, Albert Einstein Cancer Center and Montefiore Health System, Bronx, NY. The study was published online to coincide with the ASCO presentation (Sparano JA, et al. N Engl J Med. 2018;379:111-121).
It is well-known that women with a low-risk score (score, 0-10) on the Oncotype DX test can safely forego chemotherapy, and women with a high-risk score (score, 26-100) should have chemotherapy in addition to endocrine therapy; however, optimal treatment for the intermediate-risk group (score, 11-25)—for those with ER-positive, HER2-negative, node-negative early breast cancer—which involves many patients, has not been well-defined until now.
The TAILORx Study
The TAILORx study, as its name suggests, was designed to determine how best to tailor treatment for each individual patient.
“This study was not designed to just use less treatment. It was designed to tailor treatment, with the name chosen aptly, with the idea that some women are going to need more of some type of therapy and less of another, and others will get a different treatment based on the biology of their tumor,” said ASCO Expert Harold J. Burstein, MD, PhD, FASCO, Breast Oncology Program, Dana-Farber Cancer Institute, Boston. Dr Burstein was not involved in the study.
“What the data provided here from this massive, NCI-sponsored study trial show is that the vast majority of women who have this test performed on their tumor can be told that they don’t need chemotherapy, and that can be said with tremendous confidence as assurance,” Dr Burstein said.
However, there is a caveat. An exploratory analysis of the trial suggested that women age 50 years or less whose Oncotype DX risk score is 16 to 25 (still in the intermediate range) have some benefit from chemotherapy.
“Younger women with risk scores of 16 to 25 should discuss treatment with their oncologist,” Dr Sparano said. It is important to keep in mind that some women with this risk score will still benefit from chemotherapy.
TAILORx enrolled 10,273 women aged 18 to 75 years at >1100 sites in 6 countries, making this the largest breast cancer trial to be conducted to date. The patients were assigned to 1 of 4 arms based on risk score: those with a risk score of 0 to 10 (ie, low risk) were assigned to endocrine therapy alone; those with a midrange risk score of 11 to 25 were randomized to endocrine therapy alone or to endocrine therapy plus chemotherapy; and those with a risk score of 26 to 100 (high risk) received endocrine therapy plus chemotherapy.
The primary end point was survival free of invasive disease—or invasive disease–free survival (iDFS)—with a noninferiority study design.
In patients with a midrange risk score, endocrine therapy was noninferior to endocrine therapy plus chemotherapy. The 9-year iDFS rates were 83.3% for endocrine therapy and 84.3% for endocrine therapy plus chemotherapy. The overall distant recurrence rate in the group of patients with a midrange risk score was 5%, and overall survival was similar.
In the low-range risk score group, the distant recurrence rate was 3%. In the high-range risk score group, the distant recurrence rate was 13%, despite the addition of chemotherapy.
An exploratory analysis performed to look at the effect of age on patients in the midrange risk group (ie, risk score 11-25) showed that chemotherapy had some benefit in patients aged <50 years with a risk score of 16 to 25 (at the higher end of midrange). When patients with risk scores of 16 to 20 were compared with those who had risk scores of 20 to 25, there were 2% fewer recurrences for patients with scores of 16 to 20 who received chemotherapy in addition to endocrine therapy compared with 7% fewer recurrences in patients with scores of 21 to 25 who received chemotherapy plus endocrine therapy.
The conclusion was that adjuvant chemotherapy may be spared in all women aged ≥50 years with a risk score of 11 to 25 and in 36% of patients aged ≤50 years (14% of the overall study population). Among patients aged ≤50 years, 64% had a risk score of 16 to 25, and this subset can derive some benefit from chemotherapy.
“This is an extraordinary day for breast cancer doctors and women with breast cancer, because we can individualize therapy for women with early-stage ER-positive, HER2-negative, node-negative breast cancer,” Dr Burstein stated.
“This is a powerful finding. Ten-year disease-free survival was 87% for those with highest risk score group. We have made progress!” he said.
Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
As evidenced by the 2013 annual meetings of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), the pace at which scientific knowledge is influencing cancer drug development is astounding. Breakthroughs in our collective understanding of the underlying biology [ Read More ]